paper_id,claim,figure_id,title,caption,local_image_path,url
PMC10962051,"LOE was level I in 4 references (1.7%), level II in 24 references (10.1%), level III in 71 references (29.8%), level IV in 108 references (45.4%), level V in 17 references (7.1%), and unable to be determined in 14 references (5.9%) (Table 2, Figure 1).",PMC10962051_figure_1,Figure 1.,Reference level of evidence by payer.,./data/PMC10962051/images/figure_1.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adfd/10962051/24fdb28569d5/10.1177_24730114241239310-fig1.jpg
PMC10962051,"Commercial Payer
LOE I
LOE II
LOE III
LOE IV
LOE V
Unable to be Determined



Aetna
1
9
36
55
8
6


Anthem
1
10
19
19
0
1


Cigna
2
6
22
20
6
3


HCSC
0
2
3
24
4
0


Highmark
1
1
2
10
0
1


United Healthcare
1
0
1
0
0
4


Totals, n (%)
4 (1.7)
24 (10.1)
71 (29.8)
108 (45.4)
17 (7.1)
14 (5.9)



Open in a new tab
Abbreviations: HCSC, Health Care Services Corporation; LOE, level of evidence.Figure 1.",PMC10962051_figure_1,Figure 1.,Reference level of evidence by payer.,./data/PMC10962051/images/figure_1.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adfd/10962051/24fdb28569d5/10.1177_24730114241239310-fig1.jpg
PMC10962051,"Four references (1.7%) specified 6 months as length of conservative treatment, whereas 2 references (0.8%) specified 12 weeks as length of conservative treatment (Table 4, Figure 2).",PMC10962051_figure_2,Figure 2.,Number and percentage of references cited by each payer that mention their specific coverage criteria.,./data/PMC10962051/images/figure_2.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adfd/10962051/d986af32ed46/10.1177_24730114241239310-fig2.jpg
PMC10962051,"FDA Approved Implant, n (%)
Mentions Skeletal Maturity, n (%)
Failure of Conservative Management, n (%)
Severe Pain, n (%)
Loss of Function or Mobility, n (%)
Advanced Ankle Arthritis, n (%)
Arthritis of Adjacent Joints, n (%)
Severe Arthritis of Contralateral Ankle, n (%)
Arthrodesis (Fusion) of Contralateral Ankle, n (%)
Presence of Inflammatory Arthritis (eg, Rheumatoid), n (%)
Adequate Lower-Extremity Vascular Perfusion, n (%)



Aetna
61 (53.0)
10 (8.7)
2 (1.7)
44 (38.3)
35 (30.4)
104 (90.4)
10 (8.7)
16 (13.9)
11 (9.6)
81 (70.4)
35 (30.4)


Anthem
31 (62.0)
5 (10.0)
1 (2.0)
7 (14.0)
11 (22.0)
37 (74.0)
5 (10.0)
0 (0.0)
8 (16.0)
18 (36.0)
19 (38.0)


Cigna
38 (64.4)
7 (11.9)
2 (3.4)
16 (27.1)
20 (33.9)
46 (78.0)
3 (5.1)
4 (6.8)
2 (3.4)
25 (42.4)
26 (44.1)


HCSC
23 (69.7)
0 (0.0)
2 (6.1)
13 (39.4)
10 (30.3)
25 (75.8)
3 (9.1)
3 (9.1)
5 (15.2)
26 (78.8)
12 (36.4)


Highmark
4 (26.7)
1 (6.7)
1 (6.7)
6 (40.0)
4 (26.7)
14 (93.3)
1 (6.7)
0 (0.0)
0 (0.0)
12 (80.0)
3 (20.0)


United
0 (0.0)
2 (33.3)
1 (16.7)
6 (100.0)
5 (83.3)
6 (100.0)
2 (33.3)
0 (0.0)
0 (0.0)
1 (16.7)
1 (16.7)


Total
135 (56.7)
22 (9.2)
6 (2.5)
80 (33.6)
74 (31.1)
199 (83.6)
22 (9.2)
18 (7.6)
23 (9.7)
139 (58.4)
86 (36.1)



Open in a new tab
Abbreviations: FDA, US Food and Drug Administration; HCSC, Health Care Services Corporation.Figure 2.",PMC10962051_figure_2,Figure 2.,Number and percentage of references cited by each payer that mention their specific coverage criteria.,./data/PMC10962051/images/figure_2.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adfd/10962051/d986af32ed46/10.1177_24730114241239310-fig2.jpg
PMC10962051,"Ten references (8.7%) mentioned arthritis of adjacent joints, 16 references (13.9%) mentioned severe arthritis of contralateral ankle, and 11 references (9.6%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",PMC10962051_figure_2,Figure 2.,Number and percentage of references cited by each payer that mention their specific coverage criteria.,./data/PMC10962051/images/figure_2.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adfd/10962051/d986af32ed46/10.1177_24730114241239310-fig2.jpg
PMC10962051,"Two references (1.7%) mentioned the duration of conservative treatment, with both specifying 6 months (Table 4, Figure 2).Anthem
Anthem had 50 references that were analyzed, none of which were cited within the text of the coverage policy.",PMC10962051_figure_2,Figure 2.,Number and percentage of references cited by each payer that mention their specific coverage criteria.,./data/PMC10962051/images/figure_2.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adfd/10962051/d986af32ed46/10.1177_24730114241239310-fig2.jpg
PMC10962051,"Five references (10.0%) mentioned arthritis of adjacent joints, 0 references (0%) mentioned severe arthritis of contralateral ankle, and 8 references (16.0%) mentioned arthrodesis of contralateral ankle (Table 4, Figure 2).",PMC10962051_figure_2,Figure 2.,Number and percentage of references cited by each payer that mention their specific coverage criteria.,./data/PMC10962051/images/figure_2.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adfd/10962051/d986af32ed46/10.1177_24730114241239310-fig2.jpg
PMC10962051,"One reference (2.0%) mentioned duration of conservative treatment of 6 months (Table 4, Figure 2).Cigna
Cigna had 59 references that were analyzed, of which 10 were cited in the text of their coverage policy.",PMC10962051_figure_2,Figure 2.,Number and percentage of references cited by each payer that mention their specific coverage criteria.,./data/PMC10962051/images/figure_2.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adfd/10962051/d986af32ed46/10.1177_24730114241239310-fig2.jpg
PMC10962051,"Three references (5.1%) mentioned arthritis of adjacent joints, 4 references (6.8%) mentioned severe arthritis of the contralateral ankle, and 2 references (3.4%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",PMC10962051_figure_2,Figure 2.,Number and percentage of references cited by each payer that mention their specific coverage criteria.,./data/PMC10962051/images/figure_2.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adfd/10962051/d986af32ed46/10.1177_24730114241239310-fig2.jpg
PMC10962051,"Two references (3.4%) mentioned the duration of conservative treatment, with both specifying 6 months (Table 4, Figure 2).Health Care Services Corporation
Health Care Services Corporation had 33 references that were analyzed.",PMC10962051_figure_2,Figure 2.,Number and percentage of references cited by each payer that mention their specific coverage criteria.,./data/PMC10962051/images/figure_2.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adfd/10962051/d986af32ed46/10.1177_24730114241239310-fig2.jpg
PMC10962051,"Three references (9.1%) mentioned arthritis of adjacent joints, 3 references (9.1%) mentioned severe arthritis of contralateral ankle (Table 4, Figure 2).",PMC10962051_figure_2,Figure 2.,Number and percentage of references cited by each payer that mention their specific coverage criteria.,./data/PMC10962051/images/figure_2.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adfd/10962051/d986af32ed46/10.1177_24730114241239310-fig2.jpg
PMC10962051,"Two references (6.1%) mentioned the duration of conservative treatment, with both specifying 12 weeks (Table 4, Figure 2).Highmark
Highmark had 15 references that were analyzed.",PMC10962051_figure_2,Figure 2.,Number and percentage of references cited by each payer that mention their specific coverage criteria.,./data/PMC10962051/images/figure_2.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adfd/10962051/d986af32ed46/10.1177_24730114241239310-fig2.jpg
PMC10962051,"One reference (6.7%) mentioned arthritis of adjacent joints, 0 references (0%) mentioned severe arthritis of the contralateral ankle, and 0 references (0%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",PMC10962051_figure_2,Figure 2.,Number and percentage of references cited by each payer that mention their specific coverage criteria.,./data/PMC10962051/images/figure_2.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adfd/10962051/d986af32ed46/10.1177_24730114241239310-fig2.jpg
PMC10962051,"One reference (6.7%) mentioned duration of conservative treatment of 6 months (Table 4, Figure 2).United Healthcare
United Healthcare had 6 references that were analyzed, all of which were cited in the full text of the coverage policy.",PMC10962051_figure_2,Figure 2.,Number and percentage of references cited by each payer that mention their specific coverage criteria.,./data/PMC10962051/images/figure_2.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adfd/10962051/d986af32ed46/10.1177_24730114241239310-fig2.jpg
PMC10962051,"Two references (33.3%) mentioned arthritis of adjacent joints, 0 references (0%) mentioned severe arthritis of the contralateral ankle, and 0 references (0%) mentioned arthrodesis of the contralateral ankle (Table 4, Figure 2).",PMC10962051_figure_2,Figure 2.,Number and percentage of references cited by each payer that mention their specific coverage criteria.,./data/PMC10962051/images/figure_2.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adfd/10962051/d986af32ed46/10.1177_24730114241239310-fig2.jpg
PMC10962051,"One reference (16.7%) mentioned duration of conservative treatment of 6 months (Table 4, Figure 2).Discussion
The results of this study demonstrate that in their coverage policies for TAA, commercial insurance payers cite poor quality references, occasionally cite their references improperly in the policy document, and are forced to rely on low–level of evidence studies to formulate their specific coverage criteria.",PMC10962051_figure_2,Figure 2.,Number and percentage of references cited by each payer that mention their specific coverage criteria.,./data/PMC10962051/images/figure_2.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adfd/10962051/d986af32ed46/10.1177_24730114241239310-fig2.jpg
PMC10962051,"One reference (16.7%) mentioned duration of conservative treatment of 6 months (Table 4, Figure 2).",PMC10962051_figure_2,Figure 2.,Number and percentage of references cited by each payer that mention their specific coverage criteria.,./data/PMC10962051/images/figure_2.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adfd/10962051/d986af32ed46/10.1177_24730114241239310-fig2.jpg
PMC10962051,"Two references (1.7%) mentioned the duration of conservative treatment, with both specifying 6 months (Table 4, Figure 2).",PMC10962051_figure_2,Figure 2.,Number and percentage of references cited by each payer that mention their specific coverage criteria.,./data/PMC10962051/images/figure_2.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adfd/10962051/d986af32ed46/10.1177_24730114241239310-fig2.jpg
PMC10962051,"One reference (2.0%) mentioned duration of conservative treatment of 6 months (Table 4, Figure 2).",PMC10962051_figure_2,Figure 2.,Number and percentage of references cited by each payer that mention their specific coverage criteria.,./data/PMC10962051/images/figure_2.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adfd/10962051/d986af32ed46/10.1177_24730114241239310-fig2.jpg
PMC10962051,"Two references (3.4%) mentioned the duration of conservative treatment, with both specifying 6 months (Table 4, Figure 2).",PMC10962051_figure_2,Figure 2.,Number and percentage of references cited by each payer that mention their specific coverage criteria.,./data/PMC10962051/images/figure_2.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adfd/10962051/d986af32ed46/10.1177_24730114241239310-fig2.jpg
PMC10962051,"Two references (6.1%) mentioned the duration of conservative treatment, with both specifying 12 weeks (Table 4, Figure 2).",PMC10962051_figure_2,Figure 2.,Number and percentage of references cited by each payer that mention their specific coverage criteria.,./data/PMC10962051/images/figure_2.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adfd/10962051/d986af32ed46/10.1177_24730114241239310-fig2.jpg
PMC10962051,"One reference (6.7%) mentioned duration of conservative treatment of 6 months (Table 4, Figure 2).",PMC10962051_figure_2,Figure 2.,Number and percentage of references cited by each payer that mention their specific coverage criteria.,./data/PMC10962051/images/figure_2.jpg,https://cdn.ncbi.nlm.nih.gov/pmc/blobs/adfd/10962051/d986af32ed46/10.1177_24730114241239310-fig2.jpg
